More specifically, screening for MMR variants in colorectal tumors is regarded as medically necessary only for colorectal cancer patients (and then only for whose family members meet specific criteria/the revised Bethesda guidelines) (Local Coverage Determination (LCD)). This evidence concerns the gene MRC1 and colorectal cancer.